Unicycive Therapeutics Inc
UNCY
Closed
$5.63
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The company is headquartered in Los Altos, California and currently employs 21 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Key stats
Open
$5.42
Volume
642.18K
Market cap
$151.81M
Prev. close
$5.45
Impl / hst vl
-
Open interest
$0.00
$5.42
Day’s Range
$5.77
$3.93
52W Range
$8.74
Valuation
11
Valuation score
Strongly Overvalued
P/E
-
P/S
-
P/B
3.64
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
-86.57%
FCF growth
21.67
Analysts estimates
Consensus rating
Buy
The average rating from top 11 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$35.59
The top 11 analysts forecasts that 12-month price may increase by 532.09%, with a low of $13.13 and a high of $94.50
$13.13
Low
$35.59
Avg
$94.50
High
Current price
Earnings
Q2 ‘26 revenue
$0.00
Q2 ‘26 net income
-$1.72M
Revenue
Net income
Previous EPS
-$0.54
Estimate EPS
-$0.34
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply